EGFR and non-small cell lung carcinoma: The analysis showed that gefitinib is less effective in non-adenocarcinoma NSCLC harboring EGFR mutations than in adenocarcinoma harboring EGFR mutations (response rate (RR): 27% vs. 66%, P = 0.000028; DCR: 67–70% vs. 92–93%, P = 0.000014; median progression-free survival (mPFS): 3.0 vs. 9.4 months, P = 0.0001).